| 000 | 01863 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250516221652.0 | ||
| 264 | 0 | _c20150424 | |
| 008 | 201504s 0 0 eng d | ||
| 022 | _a1949-2553 | ||
| 024 | 7 |
_a10.18632/oncotarget.1990 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHerrmann, Ken | |
| 245 | 0 | 0 |
_aWeek one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. _h[electronic resource] |
| 260 |
_bOncotarget _cJun 2014 |
||
| 300 |
_a4050-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCyclophosphamide _xtherapeutic use |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aDoxorubicin _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPositron-Emission Tomography _xmethods |
| 650 | 0 | 4 |
_aPrednisone _xtherapeutic use |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aVincristine _xtherapeutic use |
| 700 | 1 | _aBuck, Andreas K | |
| 700 | 1 | _aSchuster, Tibor | |
| 700 | 1 | _aAbbrederis, Kathrin | |
| 700 | 1 | _aBlümel, Christina | |
| 700 | 1 | _aSanti, Ivan | |
| 700 | 1 | _aRudelius, Martina | |
| 700 | 1 | _aWester, Hans-Jürgen | |
| 700 | 1 | _aPeschel, Christian | |
| 700 | 1 | _aSchwaiger, Markus | |
| 700 | 1 | _aDechow, Tobias | |
| 700 | 1 | _aKeller, Ulrich | |
| 773 | 0 |
_tOncotarget _gvol. 5 _gno. 12 _gp. 4050-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.1990 _zAvailable from publisher's website |
| 999 |
_c23966679 _d23966679 |
||